International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)

Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling...

Full description

Saved in:
Bibliographic Details
Published inThe American heart journal Vol. 163; no. 1; pp. 13 - 19.e1
Main Authors Kakkar, Ajay K., Mueller, Iris, Bassand, Jean-Pierre, Fitzmaurice, David A., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Hacke, Werner, Lip, Gregory Y.H., Mantovani, Lorenzo G., Verheugt, Freek W.A., Jamal, Waheed, Misselwitz, Frank, Rushton-Smith, Sophie, Turpie, Alexander G.G.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.01.2012
Mosby
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0002-8703
1097-6744
1097-6744
DOI10.1016/j.ahj.2011.09.011

Cover

Abstract Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
AbstractList Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke. Design The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient. Summary The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.BACKGROUNDAtrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of death from AF-related stroke is doubled. Current management is often inadequate, leaving patients at risk for a potentially fatal or disabling event. The purpose of the GARFIELD registry is to evaluate the management and outcomes of patients with newly diagnosed non-valvular AF at risk for stroke.The GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.DESIGNThe GARFIELD registry is an observational, multicenter, prospective study of patients with newly diagnosed AF and one or more additional risk factors for stroke. The aim is to enroll 55,000 patients at >1,000 centers in 50 countries. Enrollment will take place in five independent, sequential, prospective cohorts. An additional retrospective validation cohort of 5,000 patients with established AF and at least one additional risk factor for stroke will be conducted in parallel with cohort one. The study started in December 2009, with a planned recruitment period of 4 years and a minimum of 2-year follow-up for each patient.The GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.SUMMARYThe GARFIELD registry will provide valuable insights into the clinical management and related outcomes of AF patients throughout many regions of the world and across the spectrum of healthcare systems. By capturing data from unselected patients treated in everyday practice, the registry has the potential to identify best practices as well as deficiencies in available treatment options for specific patient populations and to describe how therapeutic strategies, patient care, and outcomes will evolve over time.
Author Mantovani, Lorenzo G.
Jamal, Waheed
Verheugt, Freek W.A.
Turpie, Alexander G.G.
Hacke, Werner
Haas, Sylvia
Bassand, Jean-Pierre
Goto, Shinya
Lip, Gregory Y.H.
Fitzmaurice, David A.
Mueller, Iris
Kakkar, Ajay K.
Rushton-Smith, Sophie
Goldhaber, Samuel Z.
Misselwitz, Frank
Author_xml – sequence: 1
  givenname: Ajay K.
  surname: Kakkar
  fullname: Kakkar, Ajay K.
  email: akkakkar@tri-london.ac.uk
  organization: Thrombosis Research Institute, London, United Kingdom
– sequence: 2
  givenname: Iris
  surname: Mueller
  fullname: Mueller, Iris
  organization: Thrombosis Research Institute, London, United Kingdom
– sequence: 3
  givenname: Jean-Pierre
  surname: Bassand
  fullname: Bassand, Jean-Pierre
  organization: University Hospital Jean-Minjoz, Besançon, France
– sequence: 4
  givenname: David A.
  surname: Fitzmaurice
  fullname: Fitzmaurice, David A.
  organization: Primary Care Clinical Sciences, The University of Birmingham, Birmingham, United Kingdom
– sequence: 5
  givenname: Samuel Z.
  surname: Goldhaber
  fullname: Goldhaber, Samuel Z.
  organization: Harvard Medical School, Boston, MA
– sequence: 6
  givenname: Shinya
  surname: Goto
  fullname: Goto, Shinya
  organization: Tokai University, Kanagawa, Japan
– sequence: 7
  givenname: Sylvia
  surname: Haas
  fullname: Haas, Sylvia
  organization: Technical University of Munich, Munich, Germany
– sequence: 8
  givenname: Werner
  surname: Hacke
  fullname: Hacke, Werner
  organization: University Hospital of Heidelberg, Heidelberg, Germany
– sequence: 9
  givenname: Gregory Y.H.
  surname: Lip
  fullname: Lip, Gregory Y.H.
  organization: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
– sequence: 10
  givenname: Lorenzo G.
  surname: Mantovani
  fullname: Mantovani, Lorenzo G.
  organization: Federico II University of Naples, Naples, Italy
– sequence: 11
  givenname: Freek W.A.
  surname: Verheugt
  fullname: Verheugt, Freek W.A.
  organization: Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands
– sequence: 12
  givenname: Waheed
  surname: Jamal
  fullname: Jamal, Waheed
  organization: Bayer Healthcare Pharmaceuticals, Berlin, Germany
– sequence: 13
  givenname: Frank
  surname: Misselwitz
  fullname: Misselwitz, Frank
  organization: Bayer Healthcare Pharmaceuticals, Berlin, Germany
– sequence: 14
  givenname: Sophie
  surname: Rushton-Smith
  fullname: Rushton-Smith, Sophie
  organization: Thrombosis Research Institute, London, United Kingdom
– sequence: 15
  givenname: Alexander G.G.
  surname: Turpie
  fullname: Turpie, Alexander G.G.
  organization: McMaster University, Hamilton, Canada
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25762111$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/22172431$$D View this record in MEDLINE/PubMed
BookMark eNqFkt-KEzEUxoOsuN3VB_BGAiLqRWuSyWQaBaGsu3WhIKwK3oVMJtOmTZOaZJQ-hm9spn9YKLhenST8vi-c75wLcOa80wA8x2iEEWbvliO5WI4IwniE-CiXR2CAEa-GrKL0DAwQQmQ4rlBxDi5iXOYrI2P2BJwTgitCCzwAf25d0sHJZLyTFlrv5iZ1jekvQc9NTGELfQs3mdAuRfjbpAWUKZgMtKYOxtqdOL_BYOKqh7PIr_R7OLW-ztjEJaO8nHdWugTvjq7GwbTQ8Ob2evYJvplO7nant0_B41baqJ8d6iX4fnP97erzcPZlens1mQ1Vics0pEVLKK4rRSrEFENKjgukSIPa3Frd8IaNCW0KTViFyoJTxmtSNKymmKKaS1Jcgtd7303wPzsdk1ibqHRux2nfRcEx5iViY5rJlyfk0nc5MxsFLhFlBecIZ-rFgerqtW7EJpi1DFtxzDoDrw6AjEraNkinTLznyooRjHuu2nMq-BiDboUyaZdxCtJYgZHopy-WIk9f9NMXiAu0U-IT5dH8Ic2HvUbnrH8ZHURUedJKNyZolUTjzYPqjydqZY0zub2V3up4n5OIRCDxtd_IfiExzrvI2Y9swP9t8J_P_wL6--1I
CODEN AHJOA2
CitedBy_id crossref_primary_10_1016_j_ijcard_2016_01_196
crossref_primary_10_1007_s40256_019_00371_3
crossref_primary_10_1136_openhrt_2023_002506
crossref_primary_10_3399_BJGP_2021_0548
crossref_primary_10_1093_europace_euz292
crossref_primary_10_1016_j_jjcc_2022_03_006
crossref_primary_10_1161_CIRCULATIONAHA_118_035012
crossref_primary_10_1186_s12872_016_0308_1
crossref_primary_10_1007_s12325_024_02895_w
crossref_primary_10_1016_j_ijcha_2019_100461
crossref_primary_10_26442_00403660_2022_12_201994
crossref_primary_10_1016_j_amjmed_2016_06_004
crossref_primary_10_1136_bmj_2021_066450
crossref_primary_10_1371_journal_pone_0177519
crossref_primary_10_1002_clc_23279
crossref_primary_10_1016_j_jelectrocard_2019_02_011
crossref_primary_10_1161_CIRCULATIONAHA_123_068239
crossref_primary_10_1186_s12959_020_00218_x
crossref_primary_10_1002_clc_23558
crossref_primary_10_3390_healthcare11050638
crossref_primary_10_1001_jamanetworkopen_2020_0107
crossref_primary_10_1182_bloodadvances_2020003560
crossref_primary_10_1161_CIRCULATIONAHA_123_064556
crossref_primary_10_1160_TH12_06_0438
crossref_primary_10_1080_00015385_2018_1494089
crossref_primary_10_2459_JCM_0000000000001007
crossref_primary_10_3390_diagnostics13040613
crossref_primary_10_17816_cardar321821
crossref_primary_10_1016_j_ahj_2013_12_006
crossref_primary_10_1016_j_acmx_2016_11_003
crossref_primary_10_1111_jce_14176
crossref_primary_10_1136_bmjopen_2016_014579
crossref_primary_10_2174_1381612826666201210113328
crossref_primary_10_1016_j_ahj_2014_04_007
crossref_primary_10_1016_j_acmx_2016_11_006
crossref_primary_10_1517_14740338_2015_1049995
crossref_primary_10_1016_j_jsha_2012_08_001
crossref_primary_10_1016_j_acvd_2018_03_012
crossref_primary_10_1093_eurheartj_suv037
crossref_primary_10_1093_eurheartj_suv038
crossref_primary_10_1186_s12877_024_05186_9
crossref_primary_10_1016_j_ahj_2017_08_011
crossref_primary_10_1136_bmjopen_2018_025901
crossref_primary_10_1517_14740338_2015_973847
crossref_primary_10_1002_agm2_12214
crossref_primary_10_1093_eurheartj_suv035
crossref_primary_10_1161_CIRCULATIONAHA_113_003825
crossref_primary_10_1517_14656566_2014_938638
crossref_primary_10_1016_j_jacc_2020_07_045
crossref_primary_10_1160_TH13_09_0741
crossref_primary_10_1016_j_ahj_2023_06_007
crossref_primary_10_4081_btvb_2023_97
crossref_primary_10_1016_j_rccl_2020_10_015
crossref_primary_10_1136_openhrt_2024_002966
crossref_primary_10_1016_j_amjmed_2023_10_027
crossref_primary_10_1161_JAHA_118_010510
crossref_primary_10_1002_clc_23176
crossref_primary_10_1093_ehjqcco_qcaa050
crossref_primary_10_1007_s12471_016_0874_y
crossref_primary_10_1111_jth_15415
crossref_primary_10_1093_ehjqcco_qcab028
crossref_primary_10_17116_kardio202417061670
crossref_primary_10_20996_1819_6446_2023_03_07
crossref_primary_10_1186_s12959_019_0195_7
crossref_primary_10_1016_j_ijcard_2016_08_236
crossref_primary_10_1093_ehjqcco_qcx003
crossref_primary_10_1080_20009666_2019_1593781
crossref_primary_10_15690_vramn1116
crossref_primary_10_2217_fnl_15_43
crossref_primary_10_1016_j_amjmed_2023_08_019
crossref_primary_10_1093_ehjdh_ztac011
crossref_primary_10_1007_s11739_021_02672_5
crossref_primary_10_1007_s00059_020_04930_2
crossref_primary_10_1177_0003319714536980
crossref_primary_10_1002_pst_2211
crossref_primary_10_1016_j_amjmed_2019_06_008
crossref_primary_10_1371_journal_pone_0063479
crossref_primary_10_2217_fca_15_31
crossref_primary_10_1161_JAHA_124_036417
crossref_primary_10_1093_ehjqcco_qcac068
crossref_primary_10_3390_jcm10040573
crossref_primary_10_1161_JAHA_116_004037
crossref_primary_10_23736_S2724_5683_22_05891_4
crossref_primary_10_1016_j_ahj_2021_09_003
crossref_primary_10_1080_07853890_2021_1893897
crossref_primary_10_1097_MD_0000000000025725
crossref_primary_10_1161_CIRCOUTCOMES_114_001556
crossref_primary_10_1111_jth_15081
crossref_primary_10_1136_openhrt_2024_002708
crossref_primary_10_1161_JAHA_114_001179
crossref_primary_10_1136_bmjopen_2017_018905
crossref_primary_10_1093_ehjqcco_qcx030
crossref_primary_10_15829_1728_8800_2013_1_4_9
crossref_primary_10_3399_BJGP_2023_0082
crossref_primary_10_1016_j_amjmed_2016_09_012
crossref_primary_10_18087_cardio_2023_10_n2284
crossref_primary_10_1093_europace_eux193
crossref_primary_10_1160_TH16_06_0485
crossref_primary_10_1136_heartjnl_2020_318420
crossref_primary_10_1161_JAHA_118_011427
crossref_primary_10_1111_dom_15202
crossref_primary_10_2196_resprot_8523
crossref_primary_10_38109_2225_1685_2017_4_40_51
crossref_primary_10_1016_j_trsl_2017_03_004
crossref_primary_10_1186_1471_2261_13_31
crossref_primary_10_1161_CIRCOUTCOMES_114_001263
crossref_primary_10_26442_00403660_2020_09_000655
crossref_primary_10_1080_14740338_2024_2409698
crossref_primary_10_1001_jamacardio_2018_4729
crossref_primary_10_1016_j_acmx_2015_04_001
crossref_primary_10_1136_openhrt_2023_002275
crossref_primary_10_1007_s00392_022_02079_y
crossref_primary_10_1016_j_ahj_2016_03_001
crossref_primary_10_1155_2014_567026
crossref_primary_10_1177_1753944716643645
crossref_primary_10_1093_ehjqcco_qcz047
crossref_primary_10_1016_j_ijcard_2015_06_088
crossref_primary_10_3238_PersKardio_2016_03_25_06
crossref_primary_10_1093_ehjqcco_qcw058
crossref_primary_10_1093_ehjcvp_pvz076
crossref_primary_10_1136_bmjopen_2021_049933
crossref_primary_10_1136_openhrt_2022_002038
crossref_primary_10_1016_j_ccep_2013_10_006
crossref_primary_10_1111_bjh_14084
crossref_primary_10_1371_journal_pone_0191592
crossref_primary_10_1378_chest_12_1091
crossref_primary_10_1111_ijcp_14313
crossref_primary_10_1159_000352062
crossref_primary_10_1016_j_hlc_2017_05_131
crossref_primary_10_1160_TH13_12_1007
crossref_primary_10_1371_journal_pone_0259199
crossref_primary_10_1111_iju_13725
crossref_primary_10_1136_bmjopen_2017_017157
crossref_primary_10_4081_btvb_2023_84
crossref_primary_10_1002_clc_22811
crossref_primary_10_1161_CIRCOUTCOMES_115_002369
crossref_primary_10_1016_j_hrthm_2018_09_021
crossref_primary_10_1136_heartjnl_2016_309832
crossref_primary_10_1159_000478895
crossref_primary_10_1016_j_amjmed_2021_01_017
crossref_primary_10_1016_j_ijcard_2018_03_060
crossref_primary_10_2310_JIM_0b013e31828df1bf
crossref_primary_10_1093_eurheartj_ehw233
crossref_primary_10_1016_j_ijcha_2023_101302
crossref_primary_10_1016_j_ctim_2016_02_014
crossref_primary_10_1111_jcpt_12634
crossref_primary_10_1161_JAHA_117_007537
crossref_primary_10_1016_j_ajem_2016_09_047
crossref_primary_10_1136_openhrt_2015_000335
crossref_primary_10_1080_17843286_2022_2123483
crossref_primary_10_1002_clc_24109
crossref_primary_10_1016_j_jacc_2014_10_052
crossref_primary_10_1093_ehjopen_oead051
crossref_primary_10_1371_journal_pone_0164076
crossref_primary_10_1111_jep_13316
crossref_primary_10_2146_ajhp150959
crossref_primary_10_1002_joa3_12034
crossref_primary_10_1016_j_ijcard_2024_132866
crossref_primary_10_1007_s11739_020_02442_9
crossref_primary_10_1093_eurheartj_ehx730
crossref_primary_10_15829_1560_4071_2021_4635
crossref_primary_10_1016_j_jacc_2015_02_010
crossref_primary_10_1136_openhrt_2024_003109
crossref_primary_10_1093_europace_euaa172
crossref_primary_10_2217_fca_2020_0014
crossref_primary_10_38109_2225_1685_2019_4_4_85
crossref_primary_10_1007_s40265_017_0699_z
crossref_primary_10_1016_j_acvd_2014_01_001
crossref_primary_10_1055_a_1333_4448
crossref_primary_10_36740_WLek202103115
crossref_primary_10_1007_s12325_021_01670_5
crossref_primary_10_1371_journal_pone_0196666
crossref_primary_10_1007_s40256_016_0161_8
crossref_primary_10_1136_openhrt_2018_000788
crossref_primary_10_15829_1728_8800_2014_6_3_8
crossref_primary_10_1016_j_jjcc_2018_09_003
crossref_primary_10_5853_jos_2016_00157
crossref_primary_10_1253_circj_CJ_18_0655
crossref_primary_10_1002_ehf2_13156
crossref_primary_10_1016_j_ahj_2019_03_013
crossref_primary_10_1177_1747493019891516
Cites_doi 10.1378/chest.10-0134
10.1001/jama.285.18.2370
10.1093/eurheartj/ehl015
10.1016/j.ahj.2008.06.029
10.1056/NEJMoa1009638
10.1056/NEJMoa0905561
10.1093/europace/euq350
10.1016/j.jacc.2005.06.077
10.1136/bmj.39280.660567.55
10.1016/j.ahj.2009.07.035
10.1016/j.ahj.2009.08.026
10.1016/j.amjmed.2009.12.013
10.1093/eurheartj/ehm358
10.1016/j.amjcard.2008.10.017
10.1016/j.amjmed.2005.10.057
10.1016/j.jacc.2010.05.025
10.1093/europace/eun369
10.1136/bmj.d124
10.1093/eurheartj/ehq278
10.1001/jama.297.11.1197
10.1136/heart.86.5.516
10.1136/hrt.2009.190827
ContentType Journal Article
Copyright 2012 Mosby, Inc.
Mosby, Inc.
2015 INIST-CNRS
Copyright © 2012 Mosby, Inc. All rights reserved.
Copyright Elsevier Limited Jan 2012
Copyright_xml – notice: 2012 Mosby, Inc.
– notice: Mosby, Inc.
– notice: 2015 INIST-CNRS
– notice: Copyright © 2012 Mosby, Inc. All rights reserved.
– notice: Copyright Elsevier Limited Jan 2012
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QO
7RV
7TS
7X7
7XB
88C
88E
8AO
8C1
8FD
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AN0
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
K9.
KB0
M0S
M0T
M1P
M2O
MBDVC
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
Q9U
7X8
DOI 10.1016/j.ahj.2011.09.011
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Physical Education Index
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Healthcare Administration Database - QC
Medical Database
Research Library
Research Library (Corporate)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
Physical Education Index
ProQuest Central
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Research Library Prep
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6744
EndPage 19.e1
ExternalDocumentID 3238418451
22172431
25762111
10_1016_j_ahj_2011_09_011
S000287031100696X
1_s2_0_S000287031100696X
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1CY
1P~
1RT
1~.
1~5
23M
354
3O-
4.4
41~
457
4G.
53G
5GY
5RE
5VS
6J9
7-5
71M
7RV
7X7
88E
8AO
8C1
8F7
8FI
8FJ
8G5
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABPPZ
ABUWG
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIWK
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AN0
ANKPU
ANZVX
APXCP
AQUVI
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BENPR
BKEYQ
BKOJK
BLXMC
BNPGV
BNQBC
BPHCQ
BVXVI
C45
CAG
CCPQU
COF
CS3
DWQXO
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-2
G-Q
GBLVA
GNUQQ
GUQSH
HEB
HMCUK
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
J5H
K-O
KOM
L7B
M0T
M1P
M29
M2O
M41
MO0
N4W
N9A
NAPCQ
O-L
O9-
OA.
OAUVE
OBH
OHH
OHT
OL~
OVD
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q38
R2-
ROL
RPZ
SAE
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
TEORI
UGJ
UHS
UKHRP
UKR
UV1
WH7
WOW
WUQ
X7M
XCE
YOC
YYM
YYP
Z5R
ZGI
ZXP
ZY1
~G-
3V.
AACTN
AAYOK
AFCTW
AFKWA
AJOXV
AMFUW
PKN
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
CITATION
~HD
AGRNS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7TS
7XB
8FD
8FK
FR3
K9.
MBDVC
P64
PKEHL
PQEST
PQUKI
Q9U
7X8
ID FETCH-LOGICAL-c515t-43f241b7c2706c60ca830c2d0f172bd9d6824d3e2670539469b23d6b4140b9a23
IEDL.DBID .~1
ISSN 0002-8703
1097-6744
IngestDate Fri Sep 05 09:34:37 EDT 2025
Sun Sep 07 03:33:51 EDT 2025
Mon Jul 21 06:02:07 EDT 2025
Mon Jul 21 09:15:05 EDT 2025
Thu Apr 24 22:58:40 EDT 2025
Thu Sep 18 00:27:26 EDT 2025
Fri Feb 23 02:34:20 EST 2024
Sun Feb 23 10:19:24 EST 2025
Tue Aug 26 17:16:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Human
Nervous system diseases
Stroke
Arrhythmia
Atrial fibrillation
Patient
Cardiovascular disease
Risk
Anticoagulant
Excitability disorder
Cerebral disorder
Vascular disease
Heart disease
Central nervous system disease
Risk factor
Circulatory system
Cardiology
Cerebrovascular disease
International
Language English
License CC BY 4.0
Copyright © 2012 Mosby, Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c515t-43f241b7c2706c60ca830c2d0f172bd9d6824d3e2670539469b23d6b4140b9a23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 22172431
PQID 1504639901
PQPubID 2031075
PageCount 7
ParticipantIDs proquest_miscellaneous_911950684
proquest_journals_1504639901
pubmed_primary_22172431
pascalfrancis_primary_25762111
crossref_citationtrail_10_1016_j_ahj_2011_09_011
crossref_primary_10_1016_j_ahj_2011_09_011
elsevier_sciencedirect_doi_10_1016_j_ahj_2011_09_011
elsevier_clinicalkeyesjournals_1_s2_0_S000287031100696X
elsevier_clinicalkey_doi_10_1016_j_ahj_2011_09_011
PublicationCentury 2000
PublicationDate January 2012
2012
2012-01-00
2012-Jan
20120101
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: January 2012
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
– name: Philadelphia
PublicationTitle The American heart journal
PublicationTitleAlternate Am Heart J
PublicationYear 2012
Publisher Elsevier Inc
Mosby
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Mosby
– name: Elsevier Limited
References Lip, Halperin (bb0095) 2010; 123
Fitzmaurice, Hobbs, Jowett (bb0015) 2007; 335
Steg, Bhatt, Wilson (bb0075) 2007; 297
Kirchhof, Auricchio, Bax (bb0025) 2007; 28
Connolly, Ezekowitz, Yusuf (bb0060) 2009; 361
Fein, Wang, Curtis (bb0030) 2010; 56
McCabe, Johnson, Marcus (bb0040) 2009; 103
Camm, Kirchhof, Lip (bb0115) 2010; 12
Waldo, Becker, Tapson (bb0105) 2005; 46
Nabauer, Gerth, Limbourg (bb0035) 2009; 11
Nieuwlaat, Capucci, Lip (bb0045) 2006; 27
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm (bb0065) 2010; 31
Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. American Journal of Medicine 2006;119:448 e1-19.
Fox, Eagle, Gore (bb0070) 2010; 96
Go, Hylek, Phillips (bb0010) 2001; 285
Lopes, Alexander, Al-Khatib (bb0055) 2010; 159
Patel, Mahaffey, Garg (bb0110) 2011; 365
Stewart, Hart, Hole (bb0005) 2001; 86
Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 2010;159:348-53 e1.
Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-63, 63 e2.
Aguilar, Hart, Pearce (bb0085) 2007
Olesen, Lip, Hansen (bb0090) 2011; 342
Pisters, Lane, Nieuwlaat (bb0100) 2010; 138
Steg (10.1016/j.ahj.2011.09.011_bb0075) 2007; 297
Olesen (10.1016/j.ahj.2011.09.011_bb0090) 2011; 342
10.1016/j.ahj.2011.09.011_bb0020
Patel (10.1016/j.ahj.2011.09.011_bb0110) 2011; 365
10.1016/j.ahj.2011.09.011_bb0050
Pisters (10.1016/j.ahj.2011.09.011_bb0100) 2010; 138
Fitzmaurice (10.1016/j.ahj.2011.09.011_bb0015) 2007; 335
Kirchhof (10.1016/j.ahj.2011.09.011_bb0025) 2007; 28
Camm (10.1016/j.ahj.2011.09.011_bb0115) 2010; 12
10.1016/j.ahj.2011.09.011_bb0080
Waldo (10.1016/j.ahj.2011.09.011_bb0105) 2005; 46
Nabauer (10.1016/j.ahj.2011.09.011_bb0035) 2009; 11
Connolly (10.1016/j.ahj.2011.09.011_bb0060) 2009; 361
Aguilar (10.1016/j.ahj.2011.09.011_bb0085) 2007
Nieuwlaat (10.1016/j.ahj.2011.09.011_bb0045) 2006; 27
Fein (10.1016/j.ahj.2011.09.011_bb0030) 2010; 56
Lip (10.1016/j.ahj.2011.09.011_bb0095) 2010; 123
Lopes (10.1016/j.ahj.2011.09.011_bb0055) 2010; 159
McCabe (10.1016/j.ahj.2011.09.011_bb0040) 2009; 103
Stewart (10.1016/j.ahj.2011.09.011_bb0005) 2001; 86
Go (10.1016/j.ahj.2011.09.011_bb0010) 2001; 285
Fox (10.1016/j.ahj.2011.09.011_bb0070) 2010; 96
European Heart Rhythm Association (10.1016/j.ahj.2011.09.011_bb0065) 2010; 31
References_xml – volume: 86
  start-page: 516
  year: 2001
  end-page: 521
  ident: bb0005
  article-title: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
  publication-title: Heart
– volume: 31
  start-page: 2369
  year: 2010
  end-page: 2429
  ident: bb0065
  article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
  publication-title: Eur Heart J
– volume: 297
  start-page: 1197
  year: 2007
  end-page: 1206
  ident: bb0075
  article-title: One-year cardiovascular event rates in outpatients with atherothrombosis
  publication-title: JAMA
– reference: Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 2010;159:348-53 e1.
– volume: 335
  start-page: 383
  year: 2007
  ident: bb0015
  article-title: Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial
  publication-title: BMJ
– volume: 159
  start-page: 331
  year: 2010
  end-page: 339
  ident: bb0055
  article-title: Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
  publication-title: Am Heart J
– volume: 96
  start-page: 1095
  year: 2010
  end-page: 1101
  ident: bb0070
  article-title: The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE
  publication-title: Heart
– reference: Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. American Journal of Medicine 2006;119:448 e1-19.
– volume: 361
  start-page: 1139
  year: 2009
  end-page: 1151
  ident: bb0060
  article-title: Dabigatran versus warfarin in patients with atrial fibrillation
  publication-title: N Engl J Med
– volume: 138
  start-page: 1093
  year: 2010
  end-page: 1100
  ident: bb0100
  article-title: A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey
  publication-title: Chest
– volume: 28
  start-page: 2803
  year: 2007
  end-page: 2817
  ident: bb0025
  article-title: Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
  publication-title: Eur Heart J
– volume: 11
  start-page: 423
  year: 2009
  end-page: 434
  ident: bb0035
  article-title: The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management
  publication-title: Europace
– volume: 27
  start-page: 3018
  year: 2006
  end-page: 3026
  ident: bb0045
  article-title: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
  publication-title: Eur Heart J
– reference: Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-63, 63 e2.
– volume: 56
  start-page: 766
  year: 2010
  end-page: 773
  ident: bb0030
  article-title: Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry
  publication-title: J Am Coll Cardiol
– volume: 46
  start-page: 1729
  year: 2005
  end-page: 1736
  ident: bb0105
  article-title: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
  publication-title: J Am Coll Cardiol
– start-page: CD006186
  year: 2007
  ident: bb0085
  article-title: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks
  publication-title: Cochrane Database Syst Rev
– volume: 365
  start-page: 883
  year: 2011
  end-page: 891
  ident: bb0110
  article-title: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
  publication-title: N Engl J Med
– volume: 12
  start-page: 1360
  year: 2010
  end-page: 1420
  ident: bb0115
  article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
  publication-title: Europace
– volume: 103
  start-page: 535
  year: 2009
  end-page: 539
  ident: bb0040
  article-title: Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation
  publication-title: Am J Cardiol
– volume: 285
  start-page: 2370
  year: 2001
  end-page: 2375
  ident: bb0010
  article-title: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
  publication-title: JAMA
– volume: 342
  start-page: d124
  year: 2011
  ident: bb0090
  article-title: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
  publication-title: BMJ
– volume: 123
  start-page: 484
  year: 2010
  end-page: 488
  ident: bb0095
  article-title: Improving stroke risk stratification in atrial fibrillation
  publication-title: Am J Med
– volume: 138
  start-page: 1093
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0100
  article-title: A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey
  publication-title: Chest
  doi: 10.1378/chest.10-0134
– volume: 285
  start-page: 2370
  year: 2001
  ident: 10.1016/j.ahj.2011.09.011_bb0010
  article-title: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
  publication-title: JAMA
  doi: 10.1001/jama.285.18.2370
– volume: 27
  start-page: 3018
  year: 2006
  ident: 10.1016/j.ahj.2011.09.011_bb0045
  article-title: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehl015
– start-page: CD006186
  year: 2007
  ident: 10.1016/j.ahj.2011.09.011_bb0085
  article-title: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks
  publication-title: Cochrane Database Syst Rev
– ident: 10.1016/j.ahj.2011.09.011_bb0080
  doi: 10.1016/j.ahj.2008.06.029
– volume: 365
  start-page: 883
  year: 2011
  ident: 10.1016/j.ahj.2011.09.011_bb0110
  article-title: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1009638
– volume: 361
  start-page: 1139
  year: 2009
  ident: 10.1016/j.ahj.2011.09.011_bb0060
  article-title: Dabigatran versus warfarin in patients with atrial fibrillation
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0905561
– volume: 12
  start-page: 1360
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0115
  article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
  publication-title: Europace
  doi: 10.1093/europace/euq350
– volume: 46
  start-page: 1729
  year: 2005
  ident: 10.1016/j.ahj.2011.09.011_bb0105
  article-title: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2005.06.077
– volume: 335
  start-page: 383
  year: 2007
  ident: 10.1016/j.ahj.2011.09.011_bb0015
  article-title: Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial
  publication-title: BMJ
  doi: 10.1136/bmj.39280.660567.55
– volume: 159
  start-page: 331
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0055
  article-title: Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2009.07.035
– ident: 10.1016/j.ahj.2011.09.011_bb0050
  doi: 10.1016/j.ahj.2009.08.026
– volume: 123
  start-page: 484
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0095
  article-title: Improving stroke risk stratification in atrial fibrillation
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2009.12.013
– volume: 28
  start-page: 2803
  year: 2007
  ident: 10.1016/j.ahj.2011.09.011_bb0025
  article-title: Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA)
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehm358
– volume: 103
  start-page: 535
  year: 2009
  ident: 10.1016/j.ahj.2011.09.011_bb0040
  article-title: Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2008.10.017
– ident: 10.1016/j.ahj.2011.09.011_bb0020
  doi: 10.1016/j.amjmed.2005.10.057
– volume: 56
  start-page: 766
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0030
  article-title: Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2010.05.025
– volume: 11
  start-page: 423
  year: 2009
  ident: 10.1016/j.ahj.2011.09.011_bb0035
  article-title: The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management
  publication-title: Europace
  doi: 10.1093/europace/eun369
– volume: 342
  start-page: d124
  year: 2011
  ident: 10.1016/j.ahj.2011.09.011_bb0090
  article-title: Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.d124
– volume: 31
  start-page: 2369
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0065
  article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehq278
– volume: 297
  start-page: 1197
  year: 2007
  ident: 10.1016/j.ahj.2011.09.011_bb0075
  article-title: One-year cardiovascular event rates in outpatients with atherothrombosis
  publication-title: JAMA
  doi: 10.1001/jama.297.11.1197
– volume: 86
  start-page: 516
  year: 2001
  ident: 10.1016/j.ahj.2011.09.011_bb0005
  article-title: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
  publication-title: Heart
  doi: 10.1136/heart.86.5.516
– volume: 96
  start-page: 1095
  year: 2010
  ident: 10.1016/j.ahj.2011.09.011_bb0070
  article-title: The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE
  publication-title: Heart
  doi: 10.1136/hrt.2009.190827
SSID ssj0006286
Score 2.4793026
Snippet Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and the risk of...
Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 13
SubjectTerms Anticoagulants
Anticoagulants - administration & dosage
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Atrial Fibrillation - mortality
Biological and medical sciences
Blood clots
Blood. Blood coagulation. Reticuloendothelial system
Cardiac dysrhythmias
Cardiology. Vascular system
Cardiovascular
Clinical medicine
Cohort Studies
Global Health
Heart
Humans
Longitudinal Studies
Medical sciences
Multicenter Studies as Topic
Neurology
Patient Selection
Pharmacology. Drug treatments
Prospective Studies
Recruitment
Registries
Research Design
Risk Factors
Stroke
Stroke - complications
Stroke - drug therapy
Stroke - mortality
Vascular diseases and vascular malformations of the nervous system
Veins & arteries
SummonAdditionalLinks – databaseName: Public Health Database
  dbid: 8C1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bb9MwFLZgSAgJTeM2AtvkBx4AKeA4rhPzgqqxMhDjYTCpb5YviWBUSSHtD9k_5hzHSTWJFfWhVWs7aXwun4-Pz0fIC1EacDNCpbKWk1Q46VNVFz4tvVF1Zr23gWzi7Ks8vRCf55N5DLh1Ma1ysInBUPvWYYz8LQAXgd6UZe-Xv1NkjcLd1UihcZvcycAGo2KWx5sUDzx2OcJfEO1hVzPkd5kfl7GCp3rDsuwmv3R_aTp4WnVPc3EzDg3-aLZHdiOQpNN-5h-QW1XzkNw9i1vlj8jVtVgfXbRITLT2SIJFkY0BSd5oW9NYWLWjGJGlJrB40BoPAiz6NDn4jmICOjaGTu2v6h3tmQLotIGLtwbZ7JsVPR9G_dlQgJV09unkywf68uP0PHx69ZhczE6-H5-mkX8hdYByVqnIa_DvtnC8YNJJ5kyZM8c9qwH1WK-8LLnwecVlAaqsYKFtee6lFbBos8rw_AnZadqmekoonzh4SV8prDDonRU5DFjakpusBFFJCBuevnaxODlyZCz0kIV2qWHCNE6YZkrDW0Jej12WfWWObY35MKV6OHIKRlKD39jWqfhXp6qLat7pTHdcM_0tBCmRCSDDys9ynhAx9oxIpkco_7vg0TVpG_8XrgphpQ4NDgbx05ubGDUjIXT8GawEbv2YpmrXnVaB7leWIiH7vdRuxkaKMoCRz7aP_ZzcgzvlffTpgOys_qyrQ8BjK3sUlO4vf40wuw
  priority: 102
  providerName: ProQuest
Title International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
URI https://www.clinicalkey.com/#!/content/1-s2.0-S000287031100696X
https://www.clinicalkey.es/playcontent/1-s2.0-S000287031100696X
https://dx.doi.org/10.1016/j.ahj.2011.09.011
https://www.ncbi.nlm.nih.gov/pubmed/22172431
https://www.proquest.com/docview/1504639901
https://www.proquest.com/docview/911950684
Volume 163
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemISEkhPheYEx-4AGQsiWO68S8ldLSAatQxaS-Wf5IREeVVKR95X_gP-YucVJVsCGhSkma-hzXPvvOuY8fIS95pkHMcBmKQgxCboULZZG6MHNaFrFxzjRgExczMb3kHxeDxQEZdbEw6Fbp1_52TW9Wa3_nzPfm2Xq5xBjfCK10CSY9E1IsMIKdp8jrpz93bh4YetmrwFC6s2w2Pl7625XP4ilPozi-TjbdXesaeqxooS6u10UbmTS5T-55ZZIO2_Y-IAd5-ZDcvvDm8kfk1977PrqqEJxo6xAIiyIiAwK90aqgPrlqTfGtLNUNkgctMBhg1brKwT2KTuhYGIiq7_lb2qIF0GEJD680ItqXGzrval2WFFRLOjkff35PX30Yzpur14_J5WT8dTQNPQZDaEHT2YQ8KUDGm9SyNBJWRFZnSWSZiwrQfIyTTmSMuyRnIoXpLGGzbVjihOGwcTNSs-QJOSyrMj8ilA0sfITLJWYZdNbwBCrMTMZ0nAG7BCTqel9Zn6AccTJWqvNEu1IwYAoHTEVSwSkgb3qSdZud46bCrBtS1YWdwkKpQHbcRJT-jSiv_VSvVaxqpiL1BzsGhPeUexz9rwee7HFb_79wZwi7dShw3LGf2jVigJnf0MYZENr_DCsFmn90mVfbWskG8ldkPCBPW67d1Y0wZaBKPvu_Nj8nd-AbuviAVD8mh5sf2_wF6Gobc9JMRjimixSO2Qiubw3PP01ncH43nn2Z_waL_D5X
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIQHShPhPYAw_gARIGYnjOjESQtW20rJ2D2OT-mZiOxmMKimkFeJj8EX4jNwlcapJrDxNeWiU-uy0d747n8_3I-Q5T1IwM1z6Ihc9nxthfZnH1k9sKvNQW6trsInJkRie8o_T3nSD_HFnYTCt0unEWlHb0mCM_A04LhytaRC-n3_3ETUKd1cdhEYjFofZr5-wZKvejfaBvy8YGxyc7A39FlXAN2C7Fz6PcrBaOjYsDoQRgUmTKDDMBjnYcm2lFQnjNsqYiEFAJSwfNYus0ByWIlqmWOgAVP41HkUCU8iSvVVKCR7z7NxtmEpuF7XOJ0u_nLcVQ-VuEIaX2cGteVoBd_IGVuNyv7e2f4Pb5FbruNJ-I2l3yEZW3CXXJ-3W_D3y-0Jskc5KBEJaWgTdooj-gKBytMxpW8i1ohgBpmmNGkJzPHgwa9Ly4BnFhHdsDETlt-wtbZAJaL-Awcv0bDkDeaDHrtevBQU3lg5GB-N9-vJD_7i-e3WfnF4JZx6QzaIsskeEsp6BS9hMYkVDazSPoMNEJywNExBNjwTu31emLYaOmBwz5bLezhUwTCHDVCAVfHjkdUcybyqBrGvMHEuVO-IKSlmBnVpHFP-LKKtatVKpUFVMBepTHRRF5IEQK02LqUd4R9l6To1H9L8Bdy5IW_e7cBXKQmyw7cRPrV6im4keod3XoJVwqyktsnJZKVnDC4uEe-RhI7WrvhESDdzWx-v7fkZuDE8mYzUeHR0-ITfhrVkT-domm4sfy-wp-IILvVNPQEo-X_WM_wvQSWtp
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELamTpqQEOKdwBj-ABIghSWO6yRIEyq0ZWVbNRUm9ZvnlwQYVVNIK8TP4G_xq7hLnEyTWPk09UOrxnaT3p2fs313DyFPeaIAZnjqi1x0fW6E9dM8tn5iVZqH2lpdkU0cjcX-Cf8w7U43yJ8mFwbDKps5sZqobWFwj3wXHBeOaBqEu7kLizjuD98svvvIIIUnrQ2dhnI0C3avKjfmkjwOsl8_YTlX7o36IPtnjA0Hn97t-45xwDeA60ufRzkgmo4NiwNhRGBUEgWG2SAHnNc2tSJh3EYZEzEobwpLS80iKzSHZYpOFRZBADjYjAElWYdsvh2MjyctLmASaOuMg6E1Z6xVtJn6cubqiaavgjC8DCWvL1QJsstr0o3LveIKHYc3yQ3n1tJerYe3yEY2v022jtzB_R3y-8LOI50VSJO0skjJRZEbAinnaJFTV-a1pLg_TFXFKUJzTEuY1UF78B3FcHhsDJ2Kb9lrWvMW0B5IwxTq82oG2kInzahf5xScXDocDQ779Pn73qT69OIuObkS2dwjnXkxzx4QyroGXsJmKdY7tEbzCAZMdMJUmIDieiRo_n1pXKl0ZOyYySYm7kyCwCQKTAaphDePvGy7LOo6Iesas0akskmAhSlbAoqt6xT_q1NWukmnlKEsmQzkx2rLFHkJQqxDLaYe4W1P51fV_tL_fnDngra1z4VrVBZig-1G_eT5TbR26hHaXoY5Cw-i1DwrVqVMK_JhkXCP3K-19nxsJEwDp_bh-rGfkC2wfnk4Gh88Itfgplm9LbZNOssfq-wxOIpLveMskJLTqzb6vy-UdmA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+longitudinal+registry+of+patients+with+atrial+fibrillation+at+risk+of+stroke%3A+Global+Anticoagulant+Registry+in+the+FIELD+%28GARFIELD%29&rft.jtitle=The+American+heart+journal&rft.au=Kakkar%2C+Ajay+K.%2C+MBBS%2C+PhD&rft.au=Mueller%2C+Iris%2C+MD&rft.au=Bassand%2C+Jean-Pierre%2C+MD&rft.au=Fitzmaurice%2C+David+A.%2C+MD&rft.date=2012&rft.issn=0002-8703&rft.volume=163&rft.issue=1&rft.spage=13&rft.epage=19.e1&rft_id=info:doi/10.1016%2Fj.ahj.2011.09.011&rft.externalDBID=ECK1-s2.0-S000287031100696X&rft.externalDocID=1_s2_0_S000287031100696X
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00028703%2FS0002870311X00133%2Fcov150h.gif